Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi™

Published on :

Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi™ November 20, 2018 Leadiant Biosciences, Inc. formerly known as Sigma-Tau Pharmaceuticals, recently received FDA approval for Revcovi™, which provides improved treatment for patients living with ADA-SCID, better known as “Bubble Boy Disease.” The journey that lead to Revcovi is a prime example of [….]